The experience and results of cytoreductive surgery and hipec using in stage IIIA–IIIC ovarian cancer

Bondar, O. V.; Rybin, A. I.

dc.contributor.author	Bondar, O. V.	en
dc.contributor.author	Rybin, A. I.	en
dc.date.accessioned	2020-10-09T05:55:05Z
dc.date.available	2020-10-09T05:55:05Z
dc.date.issued	2020
dc.identifier.citation	Bondar O. V., RybinA. I. The experience and results of cytoreductive surgery and hipec using in stage IIIA–IIIC ovarian cancer // The 7th International scientific and practical conference “Modern science: problems and innovations”, September 20–22, 2020. SSPG Publish, Stockholm, Sweden. 2020. P. 34–40.	en
dc.identifier.uri	https://repo.odmu.edu.ua:443/xmlui/handle/123456789/8038
dc.description.abstract	Nowadays cytoreductive surgery and HIPEC is the mainstay of management of advanced stages ovarian cancer. Study was conducted to assess the effectiveness of combined treatment in IIIA–IIIC ovarian cancer, its impact on quality of life. 37 patients of main group (CRS + HIPEC) were compared with 25 patients of control group (surgery + systemic chemotherapy). The quality of life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Comparative analysis of quality of life 6 months after treatment completion did not show significant statistical difference. Combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and has less systemic toxicities than systemic chemotherapy.	en
dc.language.iso	en	en
dc.subject	ovarian cancer	en
dc.subject	treatment	en
dc.subject	HIPEC	en
dc.subject	cytoreduction	en
dc.subject	chemotherapy	en
dc.title	The experience and results of cytoreductive surgery and hipec using in stage IIIA–IIIC ovarian cancer	en
dc.type	Article	en